文献速递心脑血管急症重症综合管理与镇静镇痛

新型自动化方法检测神经丝轻链预测院外心脏骤停患者预后

Neurofilament light chain evaluated with a new automated commercially available method for outcome prediction in out-of-hospital cardiac arrest patients.
PubMed 文献 · Resuscitation · 2025-06-27
一句话结论在COMACARE试验112例院外心脏骤停患者中,Siemens Atellica检测的NfL对6个月不良预后预测的AUROC为0.97-0.98,与Simoa法相当。

本研究为COMACARE试验的事后分析,纳入112例院外心脏骤停患者,使用Siemens Atellica NfL检测2016至2017年采集的样本,并与Quanterix Simoa NF-Light法比较。以6个月时脑功能分类(CPC)3-5定义为不良预后,评估24-72小时NfL在高特异性下预测预后的准确性。Atellica NfL的AUROC为0.97-0.98,与Simoa法差异极小(-0.008至0.001)。基于有限样本量的暂定切断值:99%特异性预测不良预后在24、48、72小时分别为112、229、331 ng/L;100%敏感性预测良好预后的切断值在24、48、72小时均低于29 ng/L。作者结论认为Atellica NfL准确性似乎与更繁琐的Simoa法相当,但需更大研究确定异质性心脏骤停人群的切断值。

要点

  • 在112例院外心脏骤停患者中,Atellica NfL预测6个月不良预后(CPC 3-5)的AUROC为0.97-0.98,与Simoa法差异极小(-0.008至0.001)。
  • 基于有限样本量的暂定切断值:99%特异性预测不良预后,24小时为112 ng/L、48小时为229 ng/L、72小时为331 ng/L。
  • 100%敏感性预测良好预后的切断值在24、48、72小时均低于29 ng/L。
  • Atellica NfL自动化检测的准确性似乎与更繁琐的Simoa法相当。
  • 作者指出需更大规模研究在异质性心脏骤停人群中确定切断值。

适用人群与场景

  • COMACARE试验中的112例院外心脏骤停患者,样本采集于2016至2017年。

诊断标准与关键阈值

  • 不良预后定义为院外心脏骤停后6个月时脑功能分类(CPC)3-5。
  • 暂定切断值(基于有限样本量)预测6个月不良预后且99%特异性:24小时112 ng/L、48小时229 ng/L、72小时331 ng/L。
  • 预测良好预后且100%敏感性的切断值:24、48、72小时均低于29 ng/L。

研究设计与关键结果

  • 本研究为COMACARE试验的事后分析,纳入112例院外心脏骤停患者,使用Siemens Atellica NfL检测样本,并与Quanterix Simoa NF-Light法比较。
  • Atellica NfL预测6个月不良预后(CPC 3-5)的AUROC为0.97-0.98,与Simoa法相比差异极小(-0.008至0.001)。
  • 基于有限样本量的暂定切断值:99%特异性预测不良预后在24、48、72小时分别为112、229、331 ng/L;100%敏感性预测良好预后的切断值在24、48、72小时均低于29 ng/L。

证据类型、等级与局限

  • 证据类型:COMACARE试验的事后分析。
  • 局限:原文报告样本量有限(112例),切断值为暂定值;作者指出需更大规模研究在异质性心脏骤停人群中确定切断值。

对床旁实践的改变

  • 作者认为Atellica NfL检测的准确性似乎与更繁琐的Simoa法相当,但切断值需更大研究确定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM OF THE STUDY: The biomarker neurofilament light (NfL) measured from plasma predicts outcome at 12-72 h after out-of-hospital cardiac arrest (OHCA). We performed a post-hoc analysis of NfL using samples from 112 patients in the COMACARE trial, applying the Siemens Atellica NfL.

METHODS: We analyzed samples collected between 2016 and 2017 using the Siemens Atellica NfL and compared the results with those from the Quanterix Simoa NF-Light-method. We defined poor outcome as Cerebral Performance Category (CPC) 3-5 at six months after OHCA. We evaluated the accuracy of NfL measured at 24-72 h for outcome prediction with high specificity. We calculated the areas under the receiver operating characteristic curves (AUROC) and compared the results of the two methods.

RESULTS: The Atellica NfL showed high prognostic performance, with AUROCs (0.97-0.98) comparable to those of the Simoa NfL method with a minimal difference (-0.008-0.001). Tentative cut-off values based on this limited sample size for predicting poor outcome at six months after OHCA with 99 % specificity were 112, 229, and 331 ng/L at 24, 48 and 72 h, respectively. Cut off values for predicting good outcome with 100 % sensitivity were below 29 ng/L at 24, 48, and 72 h.

CONCLUSION: The Atellica NfL assay accuracy appears well comparable to that obtained using the more laborious Simoa method. Further larger studies are needed to determine cut-off values in heterogenous populations of cardiac arrest patients.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Pussinen C, Anttonen M, Wihersaari L, et al. Neurofilament light chain evaluated with a new automated commercially available method for outcome prediction in out-of-hospital cardiac arrest patients. Resuscitation. 2025. PMID: 40582485. doi:10.1016/j.resuscitation.2025.110698

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。